Z
Zenas BioPharma, Inc. (ZBIO)
NMS – Real Time Price. Currency in USD
18.21
-3.95 (-17.82%)
At close: Mar 27, 2026, 4:00 PM EDT
18.00
-0.21 (-1.15%)
After-hours: Mar 27, 2026, 7:39 PM EDT
Get all premium features to the best stock analysis tool
NMS – Real Time Price. Currency in USD
18.21
-3.95 (-17.82%)
At close: Mar 27, 2026, 4:00 PM EDT
18.00
-0.21 (-1.15%)
After-hours: Mar 27, 2026, 7:39 PM EDT
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 5.61 | 6.05 | 10 | |
| Quick ratio | 5.61 | 5.63 | 10 | |
| Debt to Equity | 0.33 | 0.30 | 7.0 | |
| Debt to Assets | 0.21 | 1.04 | 8.0 | |
| Interest coverage | -9.73 | -16.91 | 1.0 | |
| Weighted average score | 7.2 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | N/A | 50M | 5M | 10M | 10M |
| Gross Profit | -78K | 50M | 5M | 10M | 10M |
| Operating Income | -75M | -27M | -164M | -211M | -211M |
| Net Income | -119M | -37M | -157M | -378M | -378M |
| EBITDA | -75M | -27M | -164M | -211M | -211M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -100 | -83.56 | 1.0 |
| Next quarter | N/A | -1.4 | 1.0 |
| Current year | -6.17 | 42.83 | 5.5 |
| Next year | 568.18 | 1.88 | 6.5 |
| Weighted average score | 3.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -366.88 | -272.12 | -27.44 | 3.3 |
| Y/Y | -99.99 | -357.07 | -260.31 | -35.68 | 1.0 |
| 3y average | 336.34 | -131.52 | N/A | -94.14 | 3.3 |
| 5y average | N/A | N/A | N/A | N/A | 1.0 |
| Weighted average score | 2.2 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $110.6M significantly exceed its total debt $80.0M, ensuring strong financial flexibility
Total current assets $351.2M exceed Total current liabilities $62.6M, highlighting excellent liquidity
Debt-to-equity ratio (0.3) is well below the industry average (0.3), showcasing prudent financial management
Interest coverage ratio (-9.7x) is dangerously low, suggesting debt repayment risks
Negative free cash flow -$52.4M limits the company's ability to reinvest or pay down debt